Hiab and FSP enter into agreement on the transfer of surface treatment functions in Poland
Hiab, part of Cargotec, and FSP Finnish Steel Painting Ltd have reached an agreement about the surface treatment operations in Hiab’s Stargard multi-assembly unit in Poland as of April 2021. Following the partnership FSP will provide Hiab Poland the surface treatment services and the expertise in development techniques.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210423005017/en/
Hiab, part of Cargotec, and FSP Finnish Steel Painting Ltd have reached an agreement about the surface treatment operations in Hiab’s Stargard multi-assembly unit in Poland. (Photo: Business Wire)
The surface treatment operation in Hiab’s Stargard multi-assembly unit and its associated professionals will transfer to FSP under their current employment conditions. The purpose of the agreement is to intensify the cooperation between Hiab and FSP so that the parties can focus on their own core competencies and improve business development.
For several years, FSP has been responsible for the surface treatment of Hiab’s MULTILIFT products in Finland. We have had an intense collaboration and established joint investments with Hiab. FSP is seeking international growth. ‘Thus, intensifying the collaboration further with Hiab was an anticipated consequence’, said FSP’s Chief Executive Officer Jarno Huttunen.
The new partnership will ensure Hiab continues with the latest in desired processes and technology. The facilities are equipped with a modern, cutting edge anti-corrosion treatment production line with an option for e-coating. The number of our personnel in Poland now consists of over a hundred professionals. These factors will provide us with more prospects in the future and enhance our resilience. This of course upgrades FSP’s service level in Poland, Huttunen continued. The multi-assembly unit is in the city of Stargard, in Poland.
The extension of the cooperation between the two giants creates a competitive advantage in surface treatment quality and technological leadership.
Hiab is a part of Cargotec Corporation. Cargotec enables smarter cargo flow for a better everyday with its leading cargo handling solutions and services. Hiab is the world's leading provider of on-road load handling equipment, intelligent services, smart and connected solutions.
FSP has been Hiab’s business associate for several years. FSP's role as Hiab's surface treatment expert partner is to create added value. We believe that FSP continues to respond to our demands in both delivery accuracy and quality, said Hiab’s Barry McGrane - Senior Vice President of LM Loader Cranes
Together we will continue to increase our competitive advantage in the fields of quality and technological leadership. The objective is to improve the efficiency, innovation, reliability of the surface treatment operations in the short and long term and we look forward to strengthening the partnership between both businesses,” Barry McGrane continues.
Cargotec Hiab
Hiab is the world's leading provider of on-road load handling equipment, intelligent services, smart and connected solutions. Hiab's class-leading load handling equipment includes HIAB, EFFER and ARGOS loader cranes, LOGLIFT and JONSERED forestry and recycling cranes, MOFFETT and PRINCETON truck mounted forklifts, MULTILIFT skip loaders and hooklifts, and tail lifts under the ZEPRO, DEL, and WALTCO brands. As the industry pioneer and with a proud 75 year history, Hiab is committed to be the preferred partner and solution provider to its customers and shape the future of intelligent load handling. www.hiab.com Hiab is part of Cargotec Corporation. www.cargotec.com
FSP Finnish Steel Painting Oy
FSP Finnish Steel Painting Oy is one of Europe's leading surface treatment companies. We employ more than 300 professionals and have a turnover of approximately EUR 26 million.
We offer industrial surface treatment and related design and value-added services. Our service covers the surface treatment process throughout the product's life cycle, from the definition of operating conditions to surface treatment, inspections and post-warranty maintenance.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210423005017/en/
Contact information
Mr. Jarno Huttunen
CEO
FSP Finnish Steel Painting Oy
Tel +358 50 400 2082
jarno.huttunen@fspcorp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom